AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17179480 — intervention group
Group type: COMPARATOR
Intervention: 2 fractions of 8 Gy (2 x 8 Gy)
Number of subjects: 297
Study 14657819 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (0.5 IU/mL)
Number of subjects: 296
Study 14657819 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 296
Study 10639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclodextrin solution of itraconazole
Number of subjects: 0
Study 10639376 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole capsules
Number of subjects: 0
Study 8799519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluticasone propionate (FP)
Number of subjects: 0
Study 1463945 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression
Number of subjects: 200
Study 6469177 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet T (high butter content)
Number of subjects: 30
Study 6469177 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet P (high margarine content)
Number of subjects: 30
Study 31540616 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed at end-of-treatment
Number of subjects: 553
Study 31540616 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployed at baseline and acquired employment by end-of-treatment
Number of subjects: 553
Study 31540616 — intervention group
Group type: COMPARATOR
Intervention: Unemployed at baseline and remained unemployed by end-of-treatment
Number of subjects: 553
Study 29113548 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg + Solifenacin 10 mg per day (Group A, N = 93)
Number of subjects: 262
Study 29113548 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg + Solifenacin 20 mg (Group B, N = 83)
Number of subjects: 262
Study 29113548 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg + Placebo (Control Group C, N = 86)
Number of subjects: 262
Study 26898348 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC DPI (50/250 μg twice daily)
Number of subjects: 47
Study 26898348 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC pMDI (four puffs of 25/125 μg daily)
Number of subjects: 47
Study 26898348 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study 26898348 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients >70 years old (n = 21)
Number of subjects: 47
Study 25356992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (8-week curriculum)
Number of subjects: 50
Study 25356992 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study 23158275 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker implantation (PPI)
Number of subjects: 108
Study 20873891 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 378
Study 20873891 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 378
Study 20873891 — intervention group
Group type: EXPERIMENTAL
Intervention: MDFT-detention to community
Number of subjects: 378
Study 17148567 — intervention group
Group type: COMPARATOR
Intervention: Soy protein isolate with 0 mg isoflavones
Number of subjects: 13
Study 17148567 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate with 97.5 mg isoflavones
Number of subjects: 13
Study 17148567 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate with 135.5 mg isoflavones
Number of subjects: 13
Study 14976604 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) plus didanosine or zalcitabine
Number of subjects: 0
Study 14976604 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) monotherapy
Number of subjects: 0
Study 12370800 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate and 500 mg calcium daily (n = 8)
Number of subjects: 19
Study 12370800 — intervention group
Group type: COMPARATOR
Intervention: 500 mg calcium daily (n = 11)
Number of subjects: 19
Study 9830242 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverages
Number of subjects: 0
Study 9830242 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic beverages
Number of subjects: 0
Study 9830242 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol with pleasant photographic slides
Number of subjects: 0
Study 9830242 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic with pleasant photographic slides
Number of subjects: 0
Study 8628584 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation and imagery training
Number of subjects: 94
Study 8628584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral coping skills package (including relaxation and imagery)
Number of subjects: 94
Study 8628584 — intervention group
Group type: COMPARATOR
Intervention: Therapist support
Number of subjects: 94
Study 8628584 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 94
Study 2655606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (0.05‐0.1 mg/kg/day)
Number of subjects: 65
Study 2655606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 773494 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (three different doses taken once daily for four weeks)
Number of subjects: 0
Study 31324487 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based hand hygiene program
Number of subjects: 6
Study 31324487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6
Study 27471824 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge trocar cannula technique
Number of subjects: 18
Study 27471824 — intervention group
Group type: COMPARATOR
Intervention: Standard vitreous tap and injection technique
Number of subjects: 18
Study 26079405 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy (pravastatin) initiated in childhood, duration 10 years
Number of subjects: 214
Study 23523573 — intervention group
Group type: EXPERIMENTAL
Intervention: Thenar eminence (TE) grip
Number of subjects: 60
Study 23523573 — intervention group
Group type: COMPARATOR
Intervention: E-C clamp (EC) grip
Number of subjects: 60
Study 23523573 — intervention group
Group type: COMPARATOR
Intervention: E-C clamp (EC) grip first, then Thenar eminence (TE) grip
Number of subjects: 60
Study 23523573 — intervention group
Group type: COMPARATOR
Intervention: Thenar eminence (TE) grip first, then E-C clamp (EC) grip
Number of subjects: 60
Study 23523573 — intervention group
Group type: EXPERIMENTAL
Intervention: Thenar eminence (TE) grip (first 12 breaths)
Number of subjects: 60
Study 23523573 — intervention group
Group type: COMPARATOR
Intervention: E-C clamp (EC) grip (first 12 breaths)
Number of subjects: 60
Study 23523573 — intervention group
Group type: EXPERIMENTAL
Intervention: Both grips
Number of subjects: 60
Study 21511841 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeled volume (V(m))
Number of subjects: 1846
Study 21511841 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher modeled volume (V(m)) after adjustment for V(ant)
Number of subjects: 1846
Study 21511841 — intervention group
Group type: COMPARATOR
Intervention: V(ant) (calculated from anthropometric measurements)
Number of subjects: 1846
Study 19070418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg per day
Number of subjects: 0
Study 19070418 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus alpha‐blocker
Number of subjects: 0
Study 16796706 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole administered orally for 6 days, with fexofenadine on days 1, 3, and 6.
Number of subjects: 0
Study 16796706 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine administered alone.
Number of subjects: 0
Study 14501605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg
Number of subjects: 160
Study 14501605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Number of subjects: 160
Study 14501605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 90 mg
Number of subjects: 160
Study 14501605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene (all doses)
Number of subjects: 160
Study 14501605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 10966065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal lenses with a +1.50 D add (n = 42)
Number of subjects: 82
Study 10966065 — intervention group
Group type: COMPARATOR
Intervention: Single-vision glasses (n = 40)
Number of subjects: 82
Study 8761577 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 246
Study 8761577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 1551743 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(s) 15 Me PGF2 alpha intravesical instillation (1 mg daily for a maximum of 5 days)
Number of subjects: 19
Study 1551743 — intervention group
Group type: COMPARATOR
Intervention: 1% alum irrigation of bladder (5 ml/min for a maximum period of 72 hours)
Number of subjects: 19
Study 3553479 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐rich/Na‐poor salt (2 g twice daily for 8 days)
Number of subjects: 10
Study 3553479 — intervention group
Group type: COMPARATOR
Intervention: Common salt (CS) (2 g twice daily for 8 days)
Number of subjects: 10
Study 3553479 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐rich/Na‐poor salt
Number of subjects: 10
Study 3553479 — intervention group
Group type: COMPARATOR
Intervention: Common salt (CS)
Number of subjects: 10
Study 31394308 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal high-definition transcranial direct current stimulation (tDCS) over the right dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 20
Study 31394308 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 20
Study 31287523 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (n=922)
Number of subjects: 1846
Study 31287523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=924)
Number of subjects: 1846
Study 31287523 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine
Number of subjects: 1846
Study 31287523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1846
Study 28320895 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous congestion at 15 mmHg
Number of subjects: 20
Study 28320895 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous congestion at 30 mmHg
Number of subjects: 20
Study 28320895 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestion after 60 min
Number of subjects: 20
Study 28320895 — intervention group
Group type: COMPARATOR
Intervention: Control (noncongested arm)
Number of subjects: 20
Study 26154928 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated RRT initiation (12 hours or less from eligibility)
Number of subjects: 101
Study 26154928 — intervention group
Group type: COMPARATOR
Intervention: Standard RRT initiation (more than 12 hours from eligibility)
Number of subjects: 101
Study 24299565 — intervention group
Group type: EXPERIMENTAL
Intervention: DPT (Dpt extract)
Number of subjects: 102
Study 24299565 — intervention group
Group type: EXPERIMENTAL
Intervention: DPT+MRB (Dpt plus mixed respiratory bacterial extracts)
Number of subjects: 102
Study 24299565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 24299565 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 102
Study 21143591 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based lubricants
Number of subjects: 2453
Study 21143591 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-based lubricants
Number of subjects: 2453
Study 18999335 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 731
Study 18999335 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 731
Study 16870552 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (AT) at a dose of 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days.
Number of subjects: 11
Study 14648922 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-hemostatic therapy
Number of subjects: 0
Study 11775643 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 22
Study 11775643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9272232 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice a week for 5 weeks)
Number of subjects: 32
Study 9272232 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subfertile males)
Number of subjects: 32
Study 8496303 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of recombinant human GH (group 1)
Number of subjects: 18
Study 8496303 — intervention group
Group type: COMPARATOR
Intervention: Daily injection of recombinant human GH (group 2)
Number of subjects: 18
Study 8496303 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from continuous infusion to daily injections (group 1 during second period)
Number of subjects: 18
Study 8496303 — intervention group
Group type: COMPARATOR
Intervention: Daily injection of recombinant human GH (group 2 during second period)
Number of subjects: 18
Study 8496303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 8496303 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 18
Study 3688597 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and Substance Abuse Prevention Program (ASAP)
Number of subjects: 27
Study 3688597 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 30747899 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple hop (TH) test
Number of subjects: 68
Study 30747899 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hop (SH) test
Number of subjects: 68
Study 30747899 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover hop (XH) test
Number of subjects: 68
Study 30747899 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric hip strength tests
Number of subjects: 68
Study 30339489 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (1.5-W power, 150-mJ pulse energy, 10-Hz frequency, 500-μs pulse duration, 0.9-mm spot size)
Number of subjects: 117
Study 30339489 — intervention group
Group type: COMPARATOR
Intervention: Traditional scalpel surgery
Number of subjects: 117
Study 27151177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg/day
Number of subjects: 50
Study 27151177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25190434 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN alfa‐2a (180 µg/week) for 48 weeks (monotherapy)
Number of subjects: 218
Study 25190434 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN alfa‐2a (180 µg/week) for 48 weeks with ETV add-on (0.5 mg/daily starting at week 13)
Number of subjects: 218
Study 25190434 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN alfa‐2a (180 µg/week) for 48 weeks with ETV pretreatment (0.5 mg/daily for 24 weeks starting before peg‐IFN)
Number of subjects: 218
Study 24125796 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 419
Study 24125796 — intervention group
Group type: COMPARATOR
Intervention: CRT pacemaker
Number of subjects: 419
Study 22192866 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA or LAMA
Number of subjects: 523
Study 22192866 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA and LAMA
Number of subjects: 523
Study 22192866 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA, LAMA and ICS
Number of subjects: 523
Study 18367398 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐interference Screws fixation (Group 1)
Number of subjects: 30
Study 18367398 — intervention group
Group type: COMPARATOR
Intervention: BioTransFix femur extra cortical transverse fixation (Group 2)
Number of subjects: 30
Study 16848911 — intervention group
Group type: EXPERIMENTAL
Intervention: Early protocol with atropine at 10 and 20 mcg/kg/min of dobutamine (Groups A&B)
Number of subjects: 121
Study 16848911 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol with atropine at 40 mcg/kg/min of dobutamine (Group C)
Number of subjects: 121
Study 16848911 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of atropine (Groups A&B)
Number of subjects: 121
Study 16848911 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 121
Study 16848911 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine administration
Number of subjects: 121
Study 12776843 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet
Number of subjects: 17
Study 12776843 — intervention group
Group type: COMPARATOR
Intervention: Noncarbohydrate-restricted diet
Number of subjects: 17
Study 10831025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 42
Study 10831025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9248871 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin (10-60 mg/day)
Number of subjects: 66
Study 9248871 — intervention group
Group type: COMPARATOR
Intervention: haloperidol (2-6 mg/day)
Number of subjects: 66
Study 9248871 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin and haloperidol
Number of subjects: 66
Study 8448266 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (6 mg)
Number of subjects: 6
Study 8448266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2881975 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for general anxiety
Number of subjects: 61
Study 2881975 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic placebo
Number of subjects: 61
Study 2881975 — intervention group
Group type: COMPARATOR
Intervention: Alcohol placebo
Number of subjects: 61
Study 30282858 — intervention group
Group type: EXPERIMENTAL
Intervention: Daiokanzoto sherbets
Number of subjects: 23
Study 30282858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hangeshashinto sherbets
Number of subjects: 23
Study 30282858 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 23
Study 24714209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based mind fitness training (MMFT), 20 hours
Number of subjects: 0
Study 24714209 — intervention group
Group type: COMPARATOR
Intervention: Training as usual (control)
Number of subjects: 0
Study 23989106 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day amoxicillin (80 mg/kg/d; divided into 3 daily doses)
Number of subjects: 125
Study 23989106 — intervention group
Group type: COMPARATOR
Intervention: 10-day amoxicillin (80 mg/kg/d; divided into 3 daily doses)
Number of subjects: 125
Study 23989106 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day amoxicillin (80 mg/kg/d; divided into 3 daily doses)
Number of subjects: 125
Study 22805400 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU PPD tuberculin test
Number of subjects: 255
Study 22805400 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 IU PPD tuberculin test
Number of subjects: 255
Study 21243928 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergy immunotherapy tablet (Grazax), treatment lasted at least 8 weeks before the grass pollen season and continued until the season finished
Number of subjects: 78
Study 21243928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 19115441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioural Therapy (CBT) in addition to treatment as usual
Number of subjects: 90
Study 19115441 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 90
Study 19115441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioural Therapy (CBT)
Number of subjects: 90
Study 20540254 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous impulse system (AVIS) combined with low-molecular-weight heparins calcium (LMWHC)
Number of subjects: 76
Study 20540254 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparins calcium (LMWHC) alone
Number of subjects: 76
Study 15574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial expressions of anger
Number of subjects: 0
Study 15574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial expressions of fear
Number of subjects: 0
Study 15574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics associated with babyishness
Number of subjects: 0
Study 15574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics associated with maturity
Number of subjects: 0
Study 15574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite faces used in Study 3
Number of subjects: 0
Study 12141374 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental technicians
Number of subjects: 52
Study 12141374 — intervention group
Group type: COMPARATOR
Intervention: Porcelain process
Number of subjects: 52
Study 12141374 — intervention group
Group type: COMPARATOR
Intervention: Polishing process
Number of subjects: 52
Study 9521514 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 98
Study 9521514 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 98
Study 7805080 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 0
Study 7805080 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy
Number of subjects: 0
Study 7805080 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic treatment
Number of subjects: 0
Study 2688659 — intervention group
Group type: EXPERIMENTAL
Intervention: Information provided by phone
Number of subjects: 439
Study 2688659 — intervention group
Group type: EXPERIMENTAL
Intervention: Information provided in person at the clinic
Number of subjects: 439
Study 2688659 — intervention group
Group type: COMPARATOR
Intervention: Control group (not contacted by phone or clinic)
Number of subjects: 439
Study 1102398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma therapy
Number of subjects: 0
Study 1102398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fresh frozen plasma therapy)
Number of subjects: 0
Study 11722966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019 (5 x 10(10) organisms/d or 5 x 10(9) organisms/d)
Number of subjects: 30